Androgenetic Alopecia
Conditions
Keywords
Secretome, Platelet-Rich Plasma, Androgenetic Alopecia, Trichoscopy
Brief summary
This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital.
Detailed description
This research is an experimental study with a randomized controlled clinical design involving two intervention groups: one receiving secretome injections and the other receiving intradermal platelet-rich plasma injections. Evaluations are conducted by measuring hair density and the terminal-to-vellus hair ratio before and after treatment using trichoscopy/dermoscopy.
Interventions
BIOLOGICALSecretome
UC-MSC secretome was injected intradermally into the scalp at the alopecia site, with injections spaced 1 cm apart and administered every 2 weeks for 8 weeks
BIOLOGICALPlatelet-Rich Plasma (PRP) Injections
The centrifuged plasma solution was injected intradermally into the scalp at the alopecia site, with 0.1 ml per injection point spaced 1 cm apart, administered every 2 weeks for 8 weeks
Sponsors
PT. Prodia Stem Cell Indonesia
RS Prof. Dr. I.G.N.G Ngoerah
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
25 Years to 59 Years
Healthy volunteers
No
Inclusion criteria
* Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital. * Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital. * Female patients who are not currently pregnant or breastfeeding. * Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure. * Patients with no known allergies to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process. * Patients who are proficient in Indonesian and willing to provide written informed consent.
Exclusion criteria
* Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent. * Patients presenting with types of hair loss other than androgenetic alopecia. * Patients currently undergoing therapy with 5-alpha reductase inhibitors. * Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study. * Patients with active infections and/or active dermatitis on the scalp. * Patients with a known history of allergy to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process. * History of hypertrophic scarring or blood clotting (coagulation) disorders. * Patients unable to complete the research procedures in their entirety.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Terminal-to-Vellus Hair Ratio | Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9) | The ratio of terminal hair (thick, pigmented hair, diameter \>40 micrometer) to vellus hair (fine hair, diameter \<30 micrometer) in areas of androgenetic alopecia |
| Hair density | Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9) | The number of hairs per specific scalp area was measured in hairs/cm² |
Countries
Indonesia
Outcome results
None listed